TY - JOUR
T1 - A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis
AU - Palomino-Echeverria, Sara
AU - Huergo, Estefania
AU - Ortega-Legarreta, Asier
AU - Uson Raposo, Eva M.
AU - Aguilar, Ferran
AU - Peña-Ramirez, Carlos de la
AU - López-Vicario, Cristina
AU - Alessandria, Carlo
AU - Laleman, Wim
AU - Queiroz Farias, Alberto
AU - Moreau, Richard
AU - Fernandez, Javier
AU - Arroyo, Vicente
AU - Caraceni, Paolo
AU - Lagani, Vincenzo
AU - Sánchez-Garrido, Cristina
AU - Clària, Joan
AU - Tegner, Jesper
AU - Trebicka, Jonel
AU - Kiani, Narsis A.
AU - Planell, Nuria
AU - Rautou, Pierre Emmanuel
AU - Gomez-Cabrero, David
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Background: Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predicting scores, potentially overlooking crucial elements contributing to heterogeneity without necessarily impacting prognosis. Methods: To address patient heterogeneity, we developed ClustALL, a computational pipeline that simultaneously faces diverse clinical data challenges like mixed types, missing values, and collinearity. ClustALL enables the unsupervised identification of patient stratifications while filtering for stratifications that are robust against minor variations in the population (population-based) and against limited adjustments in the algorithm’s parameters (parameter-based). Results: Applied to a European cohort of patients with acutely decompensated cirrhosis (n = 766), ClustALL identified five robust stratifications, using only data at hospital admission. All stratifications included markers of impaired liver function and number of organ dysfunction or failure, and most included precipitating events. When focusing on one of these stratifications, patients were categorized into three clusters characterized by typical clinical features; notably, the 3-cluster stratification showed a prognostic value. Re-assessment of patient stratification during follow-up delineated patients’ outcomes, with further improvement of the prognostic value of the stratification. We validated these findings in an independent prospective multicentre cohort of patients from Latin America (n = 580). Conclusions: By applying ClustALL to patients with acutely decompensated cirrhosis, we identified three patient clusters. Following these clusters over time offers insights that could guide future clinical trial design. ClustALL is a novel and robust stratification method capable of addressing the multiple challenges of patient stratification in most complex diseases.
AB - Background: Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predicting scores, potentially overlooking crucial elements contributing to heterogeneity without necessarily impacting prognosis. Methods: To address patient heterogeneity, we developed ClustALL, a computational pipeline that simultaneously faces diverse clinical data challenges like mixed types, missing values, and collinearity. ClustALL enables the unsupervised identification of patient stratifications while filtering for stratifications that are robust against minor variations in the population (population-based) and against limited adjustments in the algorithm’s parameters (parameter-based). Results: Applied to a European cohort of patients with acutely decompensated cirrhosis (n = 766), ClustALL identified five robust stratifications, using only data at hospital admission. All stratifications included markers of impaired liver function and number of organ dysfunction or failure, and most included precipitating events. When focusing on one of these stratifications, patients were categorized into three clusters characterized by typical clinical features; notably, the 3-cluster stratification showed a prognostic value. Re-assessment of patient stratification during follow-up delineated patients’ outcomes, with further improvement of the prognostic value of the stratification. We validated these findings in an independent prospective multicentre cohort of patients from Latin America (n = 580). Conclusions: By applying ClustALL to patients with acutely decompensated cirrhosis, we identified three patient clusters. Following these clusters over time offers insights that could guide future clinical trial design. ClustALL is a novel and robust stratification method capable of addressing the multiple challenges of patient stratification in most complex diseases.
KW - ACLF
KW - Cirrhosis
KW - Clustering
KW - Complex diseases
KW - Patient heterogeneity
KW - Stratification
KW - Unsupervised learning
UR - http://www.scopus.com/inward/record.url?scp=85197348331&partnerID=8YFLogxK
U2 - 10.1186/s12967-024-05386-2
DO - 10.1186/s12967-024-05386-2
M3 - Article
C2 - 38937846
AN - SCOPUS:85197348331
SN - 1479-5876
VL - 22
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 599
ER -